PURPOSE: Study objectives were to develop, characterize, and evaluate a novel excipient for dry powder inhalation formulations in a canine model with a model compound. METHODS: Dry powder inhalation formulations of albuterol sulphate were developed and compared to a commercially available nebulizer albuterol solution formulation. In vitro analysis indicated a high fine-particle fraction (FPF, >70%) and a respirable particle size ( approximately 2.5 microm MMAD). Each inhalation formulation, including controls, was delivered targeting a deposited lung dose of 10 microg/kg albuterol. Active formulations were evaluated for pharmacokinetic (PK) profile and bronchodilatory effects in a ragweed-sensitized dog model of allergic airway responses. RESULTS: In vitro, the dextran spray-dried formulated materials showed that aerosol performance, including FPF, MMAD, glass transition temperature, and amorphous characteristics, were all largely unaffected by amount of drug loaded. Both the commercial and the dry powder formulations attenuated the ragweed-induced bronchoconstriction by 91.59 +/- 3.60 and 81.28 +/- 9.29%, respectively. The PK profiles for both albuterol formulations were similar, as were the corresponding T(max), C(max) and T(1/2). CONCLUSIONS: Results indicate that dextran 10 has promise as a novel excipient for dry powder inhalation drug delivery, in a preclinical setting, over a wide range of drug loadings.
PURPOSE: Study objectives were to develop, characterize, and evaluate a novel excipient for dry powder inhalation formulations in a canine model with a model compound. METHODS: Dry powder inhalation formulations of albuterol sulphate were developed and compared to a commercially available nebulizer albuterol solution formulation. In vitro analysis indicated a high fine-particle fraction (FPF, >70%) and a respirable particle size ( approximately 2.5 microm MMAD). Each inhalation formulation, including controls, was delivered targeting a deposited lung dose of 10 microg/kg albuterol. Active formulations were evaluated for pharmacokinetic (PK) profile and bronchodilatory effects in a ragweed-sensitized dog model of allergic airway responses. RESULTS: In vitro, the dextran spray-dried formulated materials showed that aerosol performance, including FPF, MMAD, glass transition temperature, and amorphous characteristics, were all largely unaffected by amount of drug loaded. Both the commercial and the dry powder formulations attenuated the ragweed-induced bronchoconstriction by 91.59 +/- 3.60 and 81.28 +/- 9.29%, respectively. The PK profiles for both albuterol formulations were similar, as were the corresponding T(max), C(max) and T(1/2). CONCLUSIONS: Results indicate that dextran 10 has promise as a novel excipient for dry powder inhalation drug delivery, in a preclinical setting, over a wide range of drug loadings.
Authors: Yara Banz; Trinh Cung; Elena Y Korchagina; Nicolai V Bovin; André Haeberli; Robert Rieben Journal: Xenotransplantation Date: 2005-11 Impact factor: 3.907
Authors: G Nilsson; M Johnell; C H Hammer; H L Tiffany; K Nilsson; D D Metcalfe; A Siegbahn; P M Murphy Journal: J Immunol Date: 1996-08-15 Impact factor: 5.422
Authors: Thomas Laumonier; Alexander J Walpen; Christine F Maurus; Paul J Mohacsi; Katja M Matozan; Elena Y Korchagina; Nicolai V Bovin; Bernard Vanhove; Jörg D Seebach; Robert Rieben Journal: Transplantation Date: 2003-09-15 Impact factor: 4.939
Authors: Philip J Kuehl; Alan Cherrington; Dan E Dobry; Dale Edgerton; Dwayne T Friesen; Charles Hobbs; Chet L Leach; Brice Murri; Doss Neal; David K Lyon; David T Vodak; Matthew D Reed Journal: AAPS PharmSciTech Date: 2014-08-09 Impact factor: 3.246
Authors: Kimberly B Shepard; David T Vodak; Philip J Kuehl; David Revelli; Yue Zhou; Amanda M Pluntze; Molly S Adam; Julia C Oddo; Lauren Switala; Jonathan L Cape; John M Baumann; Michael Banks Journal: AAPS PharmSciTech Date: 2021-08-31 Impact factor: 3.246